TISIDB

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	-
Function	May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001818 negative regulation of cytokine production GO:0002228 natural killer cell mediated immunity GO:0002237 response to molecule of bacterial origin GO:0002367 cytokine production involved in immune response GO:0002370 natural killer cell cytokine production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002532 production of molecular mediator involved in inflammatory response GO:0002534 cytokine production involved in inflammatory response GO:0002683 negative regulation of immune system process GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002701 negative regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002716 negative regulation of natural killer cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002719 negative regulation of cytokine production involved in immune response GO:0002727 regulation of natural killer cell cytokine production GO:0002728 negative regulation of natural killer cell cytokine production GO:0007160 cell-matrix adhesion GO:0031348 negative regulation of defense response GO:0031589 cell-substrate adhesion GO:0032496 response to lipopolysaccharide GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032689 negative regulation of interferon-gamma production GO:0045088 regulation of innate immune response GO:0045824 negative regulation of innate immune response GO:0050777 negative regulation of immune response
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD96 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CD96 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26787820	Lung Carcinoma	Inhibit immunity (NK cell function)	Blocking CD96 in Tigit(-/-)mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice.

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD96 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD96 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.17	0.643
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.078	0.914
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.35	0.545
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.083	0.821
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.362	0.754
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.646	0.653
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.251	0.0605
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	2.048	0.0699
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.408	0.738
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.96	0.0883
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.702	0.331
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.048	0.788

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD96 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD96. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD96. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD96. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD96. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD96 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD96 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD96
Name	CD96 molecule
Aliases	TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location	3p13-q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD96 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CD96